Salmeterol xinafoate

SKU: orb1223547

Description

A long-acting beta2-adrenergic receptor agonist (Ki=1.5 nM) used clinically to treat asthma and maintenance of COPD. Asthma Approved(In Vitro):Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation.(In Vivo):Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD).

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 94749-08-3
• MW: 603.745
• Purity: >98% (HPLC)
• Formula: C₃₆H₄₅NO₇
• SMILES: C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O
• Target: Adrenergic Receptor
• Solubility: DMSO: ≥ 50 mg/mL

Bioactivity

• In Vivo:
  Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD). Animal model: Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g). Dosage: Salmeterol (0.16 mg/kg) and/or Formoterol (0.32 mg/kg). Administration: The therapeutic efficacy of co-treatment was investigated in this model over a 56-day-long observation period. Result: COPD assessment test scores were markedly improved in mice with COPD.
• In Vitro:
  Salmeterol (0.001-25 μM) inhibits human T lymphocyte proliferation. Cell Proliferation Assay Cell line: Human T lymphocytes (THP-1 cells). Concentration: 0.001, 0.01, 0.05, 0.2, 1, 5, and 25 μM Incubation time: Result: The proliferation of Th2 cells was inhibited in a concentration dependent manner.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

GR-33343X xinafoate

Quick Database Links

Gene Symbol

Adrenergic Receptor